

WHAT IS CLAIMED IS:

- 420 183
5
- 1 11
1. A solution comprising about 0.01 to 0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline.
 2. The solution of claim 1 wherein the tenecteplase is in a concentration of about 0.01 to 0.04 mg/mL.
 - 10 3. The solution of claim 1 wherein the tenecteplase is in a concentration of about 0.01 to 0.03 mg/mL.
 4. The solution of claim 1 wherein the tenecteplase is in a concentration of about 0.01 to 0.02 mg/mL.
 - 15 5. The solution of claim 1 wherein the tenecteplase is in a concentration of about 0.01 to 0.015 mg/mL.
 6. The solution of claim 1 wherein the tenecteplase is in
20 sterile water for injection.
 7. A catheter comprising the solution of claim 1.

217

2 11

 8. A method for treating a pathological collection of a fibrin-rich fluid comprising exposing the fluid to an effective amount of a solution comprising about 0.01 to 0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline.
 - 30 9. The method of claim 8 wherein the tenecteplase is in sterile water for injection.
 10. The method of claim 8 wherein the fluid is exposed *in vivo* or *ex vivo*.
 - 35 11. The method of claim 8 wherein the pathological collection is contained within a catheter.

12. The method of claim 11 wherein the catheter is flushed with the solution.
- 5 13. The method of claim 12 wherein the catheter is contacted with the solution for at least about five days to remove fibrin-bound blood clots.
- 10 14. The method of claim 8 wherein the fluid is exposed in vivo by administration to a mammal.
- 15 15. The method of claim 14 wherein the mammal is a human.
16. The method of claim 14 further comprising administering to the mammal an effective amount of a co-agent for treating the pathological collection.
17. The method of claim 14 wherein the pathological collection being treated is sepsis or acute respiratory distress.
18. The method of claim 14 wherein the pathological collection is contained within a catheter.
- 25 19. The method of claim 18 wherein the pathological collection being treated is peripheral thrombosis and the catheter is indwelling.
-
20. A method for treating peripheral thrombosis in a mammal comprising delivering to the mammal via a catheter an effective amount of a solution comprising about 0.01 to 0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline.
- 35 21. The method of claim 20 wherein the catheter is placed in a blood clot in the mammal.


22. The method of claim 20 further comprising administering to the mammal an effective amount of a co-agent for treating the thrombosis.
- 5 23. The method of claim 22 wherein the co-agent is a blood thinner, anti-platelet drug, or anti-coagulant drug.
24. The method of claim 23 wherein the co-agent is heparin, warfarin, aspirin, tissue-plasminogen activator, urokinase, 10 reteplase, or a glycoprotein (GP) IIb/IIIa platelet receptor antagonist.
- 15 25. The method of claim 24 wherein the co-agent is abciximab, eptifibatide, tirofiban hydrochloride, heparin, or warfarin.
26. The method of claim 25 wherein the co-agent is administered via infusion or orally.

212
4

27. A kit comprising a container comprising lyophilized tenecteplase, a container comprising sterile water for injection or bacteriostatic water for injection, a container comprising normal saline, and instructions for reconstituting the tenecteplase with the water for injection and diluting the reconstituted tenecteplase with the normal saline to a final concentration of about 0.01 to 0.05 mg/mL of tenecteplase.

28. The kit of claim 27 wherein the container with tenecteplase contains about 10-50 mg tenecteplase, the container with water for injection contains about 2-10 mL of such water, and the instructions indicate that the tenecteplase is reconstituted to a final concentration of about 5 mg/mL.

29. The kit of claim 27 further comprising instructions for exposing the diluted reconstituted tenecteplase to a catheter in an effective amount to treat a pathological collection of a fibrin-rich fluid.



30. The kit of claim 29 wherein the pathological collection is peripheral thrombosis, sepsis, or adult respiratory distress syndrome. ||

5

4
31. The kit of claim 27 further comprising instructions for delivering the diluted reconstituted tenecteplase in an effective amount to a mammal via a catheter to treat peripheral thrombosis.

10

32. The kit of claim 31 further comprising a container comprising abciximab, eptifibatide, tirofiban hydrochloride, heparin, or warfarin with instructions for co-administration thereof in an effective amount with the diluted tenecteplase. ||

15

44
33. A kit comprising a container comprising a solution comprising about 0.01 to 0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline, and instructions for exposing the solution in an effective amount to a pathological collection of a fibrin-rich fluid. ||

20

5
34. The kit of claim 33 wherein the instructions are for delivering the solution in an effective amount to a mammal via a catheter to treat peripheral thrombosis. ||

25

214
35. The kit of claim 34 further comprising a container comprising abciximab, eptifibatide, tirofiban hydrochloride, heparin, or warfarin with instructions for co-administration thereof in an effective amount with the solution. ||

30